NCT06058585 The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
| NCT ID | NCT06058585 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | The George Institute |
| Condition | Chronic Kidney Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-09-04 |
| Primary Completion | 2028-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 1,000 participants in total. It began in 2024-09-04 with a primary completion date of 2028-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD). CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure. CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2) 3. Currently receiving standard of care treatment according to treating physician 4. Eligible for randomisation in at least one recruiting domain-specific appendix 5. Participant and treating physician are willing and able to perform trial procedures Exclusion Criteria: 1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months 2. Life expectancy less than 6 months
Contact & Investigator
Sradha Kotwal
STUDY CHAIR
The George Institute
Frequently Asked Questions
Who can join the NCT06058585 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06058585 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 1,000 participants.
Is NCT06058585 currently recruiting?
Yes, NCT06058585 is actively recruiting participants. Contact the research team at captivate@georgeinstitute.org.au for enrollment information.
Where is the NCT06058585 trial being conducted?
This trial is being conducted at Garran, Australia, Kingswood, Australia, Kogarah, Australia, New Lambton Heights, Australia and 11 additional locations.
Who is sponsoring the NCT06058585 clinical trial?
NCT06058585 is sponsored by The George Institute. The principal investigator is Sradha Kotwal at The George Institute. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.